AVBP Key Statistics, Chart & Performance
The current stock price of AVBP is 24.69 USD. In the past month the price increased by 34.26%. In the past year, price decreased by -15.62%.
AVBP Latest News, Press Relases and Analysis
AVBP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About AVBP
Company Profile
Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, licensing, and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company is headquartered in Newtown Square, Pennsylvania and currently employs 52 full-time employees. The company went IPO on 2024-01-26. The firm is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations. The company is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 candidate is focused on the treatment of solid tumors.
Company Info
ARRIVENT BIOPHARMA INC
18 Campus Blvd., Suite 100
Newtown Square PENNSYLVANIA US
Employees: 52
Phone: 12407806356
ARRIVENT BIOPHARMA INC / AVBP FAQ
Can you describe the business of ARRIVENT BIOPHARMA INC?
Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, licensing, and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company is headquartered in Newtown Square, Pennsylvania and currently employs 52 full-time employees. The company went IPO on 2024-01-26. The firm is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations. The company is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 candidate is focused on the treatment of solid tumors.
What is the current price of AVBP stock?
The current stock price of AVBP is 24.69 USD. The price increased by 1.4% in the last trading session.
Does ARRIVENT BIOPHARMA INC pay dividends?
AVBP does not pay a dividend.
What is the ChartMill rating of ARRIVENT BIOPHARMA INC stock?
AVBP has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists AVBP stock?
AVBP stock is listed on the Nasdaq exchange.
Can you provide the number of employees for ARRIVENT BIOPHARMA INC?
ARRIVENT BIOPHARMA INC (AVBP) currently has 52 employees.
What is the market capitalization of AVBP stock?
ARRIVENT BIOPHARMA INC (AVBP) has a market capitalization of 1.02B USD. This makes AVBP a Small Cap stock.
AVBP Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to AVBP. When comparing the yearly performance of all stocks, AVBP turns out to be only a medium performer in the overall market: it outperformed 58.03% of all stocks.
AVBP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AVBP. AVBP has a great financial health rating, but its profitability evaluates not so good.
AVBP Financial Highlights
Over the last trailing twelve months AVBP reported a non-GAAP Earnings per Share(EPS) of -4.24. The EPS decreased by -61.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.36% | ||
| ROE | -49.64% | ||
| Debt/Equity | 0 |
AVBP Forecast & Estimates
16 analysts have analysed AVBP and the average price target is 40.9 USD. This implies a price increase of 65.66% is expected in the next year compared to the current price of 24.69.